| The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice |
94 |
| Prenatal exposure to preeclampsia as an independent risk factor for long-term cardiovascular morbidity of the offspring |
19 |
| Predictive value of sFlt- PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37 weeks of pregnancy |
14 |
| Clinical implementation of the sFlt-1/PlGF ratio to identify preeclampsia and fetal growth restriction: A prospective cohort study |
12 |
| Prediction models for preeclampsia: A systematic review |
12 |
| Telehealth with remote blood pressure monitoring for postpartum hypertension: A prospective single-cohort feasibility study |
11 |
| Placental histopathological lesions in correlation with neonatal outcome in preeclampsia with and without severe features |
10 |
| Prospective biomarkers in preterm preeclampsia: A review |
10 |
| Prediction of adverse maternal outcomes from pre-eclampsia and other hypertensive disorders of pregnancy: A systematic review |
10 |
| The reduction in circulating levels of estrogen and progesterone in women with preeclampsia |
9 |
| Maternal pre-eclampsia and long-term offspring health: Is there a shadow cast? |
9 |
| Thrombotic microangiopathies of pregnancy: Differential diagnosis |
9 |
| Low fetal fraction of cell-free DNA predicts placental dysfunction and hypertensive disease in pregnancy |
9 |
| Preterm birth, low birthweight, and small for gestational age among women with preeclampsia: Does maternal age matter? |
8 |
| Differential expression of candidate circulating microRNAs in maternal blood leukocytes of the patients with preeclampsia and gestational diabetes mellitus |
8 |
| Association of gene polymorphisms of aldosterone synthase and angiotensin converting enzyme in pre-eclamptic South African Black women |
8 |
| The predictive value of the sFlt-1/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies |
8 |
| Aberrant pro-atrial natriuretic peptide/corin/natriuretic peptide receptor signaling is present in maternal vascular endothelium in preeclampsia |
7 |
| Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors - Treatment or hypertension related? An observational cohort study |
7 |
| Angiogenic biomarkers in triage and risk for preeclampsia with severe features |
7 |
| The impact of female fetal sex on preeclampsia and the maternal immune milieu |
7 |
| First-trimester mean arterial blood pressure and the risk of preeclampsia: The Great Obstetrical Syndromes (GOS) study |
6 |
| Leptin and Adiponectin as markers for preeclampsia in obese pregnant women, a cohort study |
6 |
| Decidual cells from women with preeclampsia exhibit inadequate decidualization and reduced sFlt1 suppression |
6 |
| Renal natural killer cell activation and mitochondrial oxidative stress; new mechanisms in AT1-AA mediated hypertensive pregnancy |
6 |
| Severe anemia, sickle cell disease, and thalassemia as risk factors for hypertensive disorders in pregnancy in developing countries |
6 |
| Resting-state functional connectivity in children born from gestations complicated by preeclampsia: A pilot study cohort |
6 |
| Cardiac maladaptation in term pregnancies with preeclampsia |
6 |
| Changes in endothelial cell specific molecule 1 plasma levels during preeclamptic pregnancies compared to healthy pregnancies |
6 |
| Risk of hypertension and abnormal biomarkers in the first year postpartum associated with hypertensive disorders of pregnancy among overweight and obese women |
6 |
| Sulforaphane improves endothelial function and reduces placental oxidative stress in vitro |
6 |
| A clinical evaluation of placental growth factor in routine practice in high-risk women presenting with suspected pre-eclampsia and/or fetal growth restriction |
6 |
| Placental Growth Factor informed management of suspected pre-eclampsia or fetal growth restriction: The MAPPLE cohort study |
6 |
| Pregnancy outcomes following home blood pressure monitoring in gestational hypertension |
5 |
| Assessment of novel cardiovascular biomarkers in women with a history of recurrent miscarriage |
5 |
| The hemoglobin degradation pathway in patients with preeclampsia - Fetal hemoglobin, heme, heme oxygenase-1 and hemopexin - Potential diagnostic biomarkers ? |
5 |
| Cardiovascular biomarkers in the years following pregnancies complicated by hypertensive disorders or delivered preterm |
5 |
| Preeclampsia: Disease biology and burden, its management strategies with reference to India |
5 |
| Temporal and external validation of the fullPIERS model for the prediction of adverse maternal outcomes in women with pre-eclampsia |
5 |
| Relationship between low maternal vitamin D status and the risk of severe preeclampsia: A case control study |
5 |
| Methyldopa versus nifedipine or no medication for treatment of chronic hypertension during pregnancy: A multicenter randomized clinical trial |
5 |
| Circular RNA expression profiling identifies hsa_circ_0011460 as a novel molecule in severe preeclampsia |
5 |
| Hypertensive disorder of pregnancy prevalence and associated factors among pregnant women attending ante natal care at Gondar town health Institutions, North West Ethiopia 2017 |
4 |
| Serum cystatin-c as predictive factor of preeclampsia: A meta-analysis of 27 observational studies |
4 |
| Vegetable dietary pattern associated with low risk of preeclampsia possibly through reducing proteinuria |
4 |
| Risk of abnormal fetal growth in women with early- and late-onset preeclampsia |
4 |
| First trimester placental vascularization and angiogenetic factors are associated with adverse pregnancy outcome |
4 |
| The apelinergic-axis in human preeclamptic pregnancies: A systematic review |
4 |
| Low-flow mediated constriction as a marker of endothelial function in healthy pregnancy and preeclampsia: A pilot study |
4 |
| Mean platelet volume values in preeclampsia: A systematic review and meta-analysis |
4 |
